EMPIRICA LOGIC RESEARCH INTELLIGENCE

Key Talking Points | January 2026

TOPIC: Menopausal Hormone Therapy—Risks, Benefits, and Emerging Options

PURPOSE: Quick reference for clinical team and patient consultations

TALKING POINTS:

- MHT reduces hot flashes by approximately 75% compared to placebo—significantly more effective than any non-hormonal alternative. Recent evidence confirms MHT as the most effective treatment for moderate-to-severe vasomotor symptoms, with symptom relief typically beginning within 2-4 weeks. This makes MHT the gold standard first-line therapy for appropriately selected symptomatic women under 60 or within 10 years of menopause.

- Timing matters: the "window of opportunity" is real. Studies including ELITE and KEEPS demonstrate that MHT initiated within 10 years of menopause shows a more favorable cardiovascular and overall safety profile compared to initiation at older ages or many years after menopause. This timing hypothesis has fundamentally changed how we approach MHT prescribing and patient selection.

- Transdermal beats oral for safety in at-risk women. Large population studies show transdermal estradiol is NOT associated with increased VTE risk, while oral estrogen increases VTE risk by approximately 58%. For women with cardiovascular risk factors, hypertension, migraine with aura, elevated triglycerides, or obesity, transdermal estradiol should be strongly preferred over oral formulations.

- Not all progestogens are created equal for breast cancer risk. Long-term WHI data showed estrogen-alone therapy after hysterectomy was associated with LOWER breast cancer incidence and mortality. For combined therapy, estradiol-dydrogesterone demonstrated the lowest associated increase in breast cancer risk among progestogens studied, while medroxyprogesterone acetate showed a higher risk with longer duration of use.

- Low-dose vaginal estrogen is highly effective and safe for genitourinary symptoms. Approximately 50-70% of postmenopausal women experience genitourinary syndrome of menopause (GSM). Local vaginal estrogen provides excellent relief with minimal systemic absorption and typically requires no concurrent progestogen at recommended doses. This can be safely used even in women on tamoxifen or with a prior stroke.

- Bone protection is real and significant. MHT prevents early postmenopausal bone loss and reduces fracture risk, even at ultra-low doses. A study of 0.5 mg 17β-estradiol plus 0.1 mg norethisterone acetate showed protective effects on bone turnover markers. While not first-line for osteoporosis treatment per most guidelines, it's an important benefit for symptomatic women under 60 requiring therapy.

- Route selection directly impacts cardiovascular and stroke risk. Recent nationwide cohort data found that while oral estrogen was associated with increased ischemic stroke risk, transdermal estrogen was NOT associated with excess stroke risk, and low-dose vaginal estrogen was associated with LOWER risk. This evidence supports route-specific prescribing based on individual patient cardiovascular profiles.

- Estetrol (E4) represents a promising future option with unique properties. Phase II trials showed E4 at 15 mg daily effectively reduced vasomotor symptoms with minimal hepatic impact on hemostatic parameters. E4 has high oral bioavailability, favorable pharmacology, and early signals suggesting improved safety, though long-term cardiovascular, thrombotic, and breast cancer data are still pending from ongoing studies.

RESEARCH SOURCE CITATION

Title: Menopausal Hormone Therapy—Risks, Benefits and Emerging Options: A Narrative Review

Authors: Ana Maria Arnautu, MD; Vanda Roxana Nimigean, DDS, PhD; Claudia Alexandra Nacea-Radu, MD; Dana Mihaela Tilici, MD, PhD; Diana Loreta Paun, MD, PhD

Source: International Journal of Molecular Sciences

Publication Date: November 2025

DOI: https://doi.org/10.3390/ijms262211098